FDA, Friends identify next steps for dose optimization, pragmatic trials, academic-led studies for drug approvals December 15, 2023Vol.49 No.46By Matthew Bin Han Ong
Drugs & Targets FDA approves Iwilfin for adult and pediatric patients with high-risk neuroblastoma December 15, 2023Vol.49 No.46
As Bertagnolli steps in, NIH and FDA reenvision clinical trials and evidence generation December 08, 2023Vol.49 No.45By Matthew Bin Han Ong
Drugs & Targets FDA grants Fast Track designation to Alpha1H for non-muscle invasive bladder cancer December 08, 2023Vol.49 No.45
Clinical Roundup FDA investigating serious risk of T-cell malignancy following BCMA-directed or CD19-directed autologous CAR T-cell immunotherapies December 01, 2023Vol.49 No.44
Drugs & Targets FDA approves Xtandi for non-metastatic castration-sensitive prostate cancer with biochemical recurrence December 01, 2023Vol.49 No.44
Drugs & Targets FDA grants Breakthrough Therapy Designation to epcoritamab-bysp December 01, 2023Vol.49 No.44
White House As Biden invokes wartime powers to regulate AI, oncology braces for fundamental change November 17, 2023Vol.49 No.43By Matthew Bin Han Ong
